Clinical AI is now financed like a sales engine, not a moonshot: most of Heidi's $340M is revenue-based lending.
Heidi's Sept 22 round splits into $100M of equity and $240M of growth financing from General Catalyst's Customer Value Fund. That fund pays for sales and marketing and takes a capped share of revenue.
Lenders fund sales only when customers renew in predictable ways. So buyers for clinical documentation AI look real. The small equity slice means investors are less sure about long-run margins.
Incumbents are moving into the money. Oracle Health announced five AI tools for billing and prior authorization on Sept 23, with no dates or prices. The governing signal is Capital Flood, now in a more disciplined form.
Two or more clinical AI companies raise $200M or more in pure equity at doubled valuations before March 31, 2027, with no revenue-based component.
